Evidence map›Paper›PMID 25278219›Full record

ArticleThe Lancet. Infectious diseases2014

Treating MERS-CoV during an outbreak.

Christopher M Coleman, Matthew B Frieman

Abstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Critical care medicine for emerging Middle East respiratory syndrome: Which point to be considered?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Christopher M ColemanDepartment of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA.
Matthew B FriemanDepartment of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.

Funding

Role of the Epithelial Growth Factor Receptor in SARS Coronavirus PathogenesisR01AI095569 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRIEMAN, MATTHEW BRYAN · 2011 to 2016
$2.3M
NIAID NIH HHS R01 AI095569
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCoronavirus InfectionsFemaleHumansInterferon-alphaInterferon alpha-2MaleMiddle East Respiratory Syndrome CoronavirusRecombinant ProteinsRibavirinAntiviral AgentsInterferon-alphaInterferon alpha-2Recombinant ProteinsRibavirin

Identifiers

PMID25278219
PMCPMC7128167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.